Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.58 |
| ▸ | MAOB | P27338 | 8/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11636342 | 0.84 | CYP19A1 (0.50) | KDM4EHSD17B10ALDH1A1HPGDABCG2 | |
| SCHEMBL2879029 | 0.82 | ABCG2 (0.67) | KDM4EHSD17B10ALDH1A1HPGDABCG2 | |
| SCHEMBL3364494 | 0.81 | MEN1 (0.65) | KDM4EHSD17B10ALDH1A1HPGDABCG2 | |
| SCHEMBL6703206 | 0.81 | MAOB (0.59) | KDM4EHSD17B10ALDH1A1HPGDABCG2 | |
| SCHEMBL7604105 | 0.80 | CYP19A1 (0.49) | KDM4EHSD17B10ALDH1A1HPGDABCG2 | |
| SCHEMBL10425232 | 0.80 | ABCG2 (0.60) | KDM4EHSD17B10ALDH1A1HPGDABCG2 | |
| SCHEMBL31572407 | 0.79 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDABCG2 | |
| SCHEMBL5967634 | 0.79 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDABCG2 | |
| SCHEMBL126041 | 0.79 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDABCG2 | |
| SCHEMBL10360963 | 0.78 | MAOB (0.59) | KDM4EHSD17B10MAPTCYP19A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152601-A1 | Compositions and Methods for the Treatment of Sexual Dysfunctions | THE JONATHAN HURT LIVING TRUST (US) | 2025-05-15 | — | — | US | disclosed |
| CN-106715463-B | Glycated peptide compositions and uses thereof | 苏塞克斯研究实验室 | 2020-10-16 | — | — | CN | disclosed |
| US-10472315-B2 | Inhibitors of methionine aminopeptidases and methods of treating disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-11-12 | — | — | US | disclosed |
| US-8440691-B2 | Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBVIE INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2527339-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | Abbott Laboratories (US) | 2012-11-28 | — | — | EP | disclosed |
| US-20120196852-A1 | INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-08-02 | — | — | US | disclosed |
| US-20110152250-A1 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011017519-A2 | INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-02-10 | — | — | WO | disclosed |
| US-7812019-B2 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBOTT LABORATORIES (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1844038-A2 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1625150-B9 | TRIPEPTIDES AND DERIVATIVES THEREOF FOR COSMETIC APPLICATION IN ORDER TO IMPROVE SKIN STRUCTURE | PENTAPHARM AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| EP-1625150-B1 | TRIPEPTIDES AND DERIVATIVES THEREOF FOR COSMETIC APPLICATION IN ORDER TO IMPROVE SKIN STRUCTURE | PENTAPHARM AG (CH) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006065484-A2 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| EP-1625150-A1 | TRIPEPTIDES AND DERIVATIVES THEREOF FOR COSMETIC APPLICATION IN ORDER TO IMPROVE SKIN STRUCTURE | Pentapharm AG (CH) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004099237-A1 | TRIPEPTIDES AND DERIVATIVES THEREOF FOR COSMETIC APPLICATION IN ORDER TO IMPROVE SKIN STRUCTURE | PENTAPHARM AG (CH) | 2004-11-18 | — | — | WO | disclosed |
| WO-2003057210-A1 | COMPOSITIONS AND METHODS FOR INCREASING CELL PROLIFERATION COMPRISING A FLAVONOID | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030125264-A1 | Methods For Treating Wounds | KIMBERLY-CLARK WORLDWIDE, INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | CACNA1E, CACNA1D, CACNA1S | KDM4E 2690/4885HSD17B10 3959/4885ALDH1A1 1499/4885 |
| US-20120196852-A1 | INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS | METAP1, METAP2, ENPEP | KDM4E 3317/4885HSD17B10 683/4885ALDH1A1 1430/4885 |
| US-20110152250-A1 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF | CACNA1E, CACNA1D, CACNA1S | KDM4E 2690/4885HSD17B10 3959/4885ALDH1A1 1499/4885 |
| US-20030125264-A1 | Methods For Treating Wounds | FGF2, MMP1, FIBP | KDM4E 2309/4885HSD17B10 2250/4885ALDH1A1 2440/4885 |
| US-10472315-B2 | Inhibitors of methionine aminopeptidases and methods of treating disorders | METAP1, METAP2, ENPEP | KDM4E 3317/4885HSD17B10 683/4885ALDH1A1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.